Eye drug dosing showdown: can fewer injections still control wet AMD?
NCT ID NCT04679935
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 37 times
Summary
This study compared two different dosing schedules of brolucizumab (Beovu) in 52 people with wet age-related macular degeneration (AMD) who had not responded well to previous treatment. Participants received the drug as an eye injection either on a fixed schedule or with adjustments based on their eye health. The goal was to see which schedule better maintained vision and controlled the disease over 52 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Regensburg, Bavaria, 93053, Germany
-
Novartis Investigative Site
Frankfurt am Main, Hesse, 60549, Germany
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Bonn, 53105, Germany
-
Novartis Investigative Site
Düsseldorf, 40225, Germany
-
Novartis Investigative Site
Göttingen, 37075, Germany
-
Novartis Investigative Site
Hanover, 30625, Germany
-
Novartis Investigative Site
Homburg, 66421, Germany
-
Novartis Investigative Site
Leipzig, 04103, Germany
-
Novartis Investigative Site
Lübeck, 23538, Germany
-
Novartis Investigative Site
Magdeburg, 39120, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
-
Novartis Investigative Site
Marburg, 35039, Germany
-
Novartis Investigative Site
Münster, 48149, Germany
-
Novartis Investigative Site
Neubrandenburg, 17036, Germany
-
Novartis Investigative Site
Ulm, 89075, Germany
-
Novartis Investigative Site
Lausanne, CHE, 1000, Switzerland
-
Novartis Investigative Site
Bern, 3007, Switzerland
-
Novartis Investigative Site
Zurich, 8063, Switzerland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brolucizumab (Beovu), an anti-VEGF drug given as an eye injection
What this could lead to
If successful, this could help doctors choose a better dosing schedule for brolucizumab to control wet AMD with fewer injections.
What could go wrong
This is a small, completed Phase 4 study with only 52 participants, so results may not apply to all patients. The drug can cause eye inflammation or other side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.